Silvana Martino
YOU?
Author Swipe
View article: Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index
Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index Open
Importance The Breast Cancer Index (BCI) previously identified premenopausal patients with tumors in which the ratio of expression of HOXB13 relative to IL17BR (hereafter, BCI [H/I]–low tumors) as likely to derive greatest benefit from ova…
View article: Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Open
Importance Adjuvant ovarian function suppression (OFS) with oral endocrine therapy improves outcomes for premenopausal patients with hormone receptor–positive (HR + ) breast cancer but adds adverse effects. A genomic biomarker for selectin…
View article: Supplementary Figure 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
PDF file - 72K, Box plots (with center line at the median and box edges at the quartiles) showing the raw distribution of GRB7, ERBB2, KRT19 and PHB expression for the triple negative (TN) subset, hormone receptor negative (HR-), HER2-posi…
View article: Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer Open
Purpose: To perform an exploratory analysis of the relationship between gene expression and recurrence in operable hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–normal breast cancer patients treated…
View article: Supplementary Figure 2 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Supplementary Figure 2 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Open
Supplementary Figure 2 - PDF file 9846K, Patient Flow Diagram for N9831 MYC IHC Analysis
View article: Supplementary Table 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
PDF file - 21K, Triple negative higher expression.
View article: Supplementary Figure 1 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Supplementary Figure 1 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Open
Supplementary Figure 1 - PDF file 5863K, NCCTG N9831 Trial Incorporating Trastuzumab in Adjuvant Therapy
View article: Supplementary Figure 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
PDF file - 72K, Box plots (with center line at the median and box edges at the quartiles) showing the raw distribution of GRB7, ERBB2, KRT19 and PHB expression for the triple negative (TN) subset, hormone receptor negative (HR-), HER2-posi…
View article: Supplementary Table 3 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table 3 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
PDF file - 20K, Triple negative lower expression.
View article: Data from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Data from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
Purpose: To conduct an exploratory analysis of the relationship between gene expression and recurrence in patients with operable triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin-containing chemotherapy.Exper…
View article: Supplementary Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
Supplementary Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer Open
Supplementary Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
View article: Supplementary Table 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
PDF file - 21K, Triple negative higher expression.
View article: Supplementary Tables 1-5 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Supplementary Tables 1-5 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Open
Supplementary Tables 1-5 - PDF file 91K, Supplementary Table 1. Patient Characteristics by IHC cMYC Cohort vs Non-Cohort; Supplementary Table 2. Correlation of MYC Nuclear Staining with HER2 FISH - Overall; Supplementary Table 3. Correlati…
View article: Data from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Data from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Open
Purpose: This study investigated the association between tumor MYC protein expression and disease-free survival (DFS) of patients randomized to receive chemotherapy alone (Arm A) or chemotherapy with sequential (Arm B) or concurrent…
View article: Supplementary Table 3 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table 3 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
PDF file - 20K, Triple negative lower expression.
View article: Supplementary Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
Supplementary Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer Open
Supplementary Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
View article: Supplementary Table 1 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table 1 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
XLS file - 31K, Patient characteristics by GRB7 expression.
View article: Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer Open
Purpose: To perform an exploratory analysis of the relationship between gene expression and recurrence in operable hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–normal breast cancer patients treated…
View article: Supplementary Figure 1 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Supplementary Figure 1 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Open
Supplementary Figure 1 - PDF file 5863K, NCCTG N9831 Trial Incorporating Trastuzumab in Adjuvant Therapy
View article: Data from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Data from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
Purpose: To conduct an exploratory analysis of the relationship between gene expression and recurrence in patients with operable triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin-containing chemotherapy.Exper…
View article: Supplementary Figure 1 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure 1 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
PDF file - 49K
View article: Supplementary Figure 2 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Supplementary Figure 2 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Open
Supplementary Figure 2 - PDF file 9846K, Patient Flow Diagram for N9831 MYC IHC Analysis
View article: Supplementary Table 1 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table 1 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
XLS file - 31K, Patient characteristics by GRB7 expression.
View article: Data from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Data from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Open
Purpose: This study investigated the association between tumor MYC protein expression and disease-free survival (DFS) of patients randomized to receive chemotherapy alone (Arm A) or chemotherapy with sequential (Arm B) or concurrent…
View article: Supplementary Tables 1-5 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Supplementary Tables 1-5 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Open
Supplementary Tables 1-5 - PDF file 91K, Supplementary Table 1. Patient Characteristics by IHC cMYC Cohort vs Non-Cohort; Supplementary Table 2. Correlation of MYC Nuclear Staining with HER2 FISH - Overall; Supplementary Table 3. Correlati…
View article: Supplementary Figure 1 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure 1 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
PDF file - 49K
View article: Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women Open
View article: Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Mapeando Facciones y Liderazgos al Interior de un Complejo Habitacional
Mapeando Facciones y Liderazgos al Interior de un Complejo Habitacional Open
En el presente artículo se analizan las formas de organización del poder en un determinado enclave urbano articuladas en relaciones conflictivas que redefinen los espacios simbólicos del habitar. Estas permiten poner en entredicho las cons…